News

Andrew Engeli explains Ginkgo's role in the €24 million EU-Funded RANGER project for emerging infectious disease surveillance and response.

In a novel, natural experiment associated with age and the antiviral, investigators were able to see the effects of the therapy in a group of adults considered to be more at risk for hospitalization and death.

Sean Ong discusses how persistent fever beyond 72 hours emerges as a stronger predictor of mortality in MRSA bacteremia compared to CRP and WBC counts.

Oliver A Cornely shares guidance on tackling Candida infections in an evolving landscape, including rising resistance and taxonomic changes.

The company’s investigational gel, RECCE 327, met primary and secondary endpoints, and it plans to progress to a phase 3 trial.

Elke Wollants explains how wastewater surveillance in Belgium provided an early warning for measles outbreaks, offering insights into broader virus circulation.

The trial is being conducted by LimmaTech Biologics, and the first participants have been vaccinated.

Confirmed measles cases in Texas have risen from 24 to 58 in just six days, with 13 hospitalizations reported.

The Prescription Drug User Fee Act (PDUFA) date is set for June 19. And if it is approved, it would be the first and only twice-yearly HIV pre-exposure prophylaxis (PrEP).

Emily Ricotta, PhD, MSc outlines the importance of involving affected populations and refining data collection methods to improve early decision-making during epidemics

A state official says the woman is hospitalized in another state, and had preexisting health conditions that can make people more vulnerable to illness.

Koos Korsten, MD, PhD, MSc discusses how clinical context, including prevalence and outbreak situations, influences the choice between PCR and culture-based diagnostics for Candidozyma auris.

The company's trivalent vaccine (mRNA-1403) was being studied in a phase 3 trial.

Emily Ricotta, PhD, MSc, discusses how observational studies shape early decisions and address challenges in infectious disease outbreaks

In a statement, the official, Ralph Abraham, MD, along with the state’s deputy surgeon general, wrote that because of “COVID missteps” they will no longer encourage vaccination to people.

This week, five all-oral TB regimens showed efficacy, fungal biofilm diseases remain challenging, over 2 million pastries were recalled due to contamination, and more.

In the Phase 3 trial, GSK's vaccine met all 11 primary endpoints, providing expanded options for preventing invasive meningococcal disease in individuals aged 10-25 years.

The approval is based on positive phase 3 clinical trial results, offering an effective option for travelers and others at risk of chikungunya, the mosquito-borne illness.

Su H Wang, MD, FACP, MPH discusses combating vaccine misinformation, preventing outbreaks, and highlighting global health interconnectedness

Su H Wang, MD, FACP, MPH, cautions that the US withdrawal from the WHO and cuts to critical health programs may reverse progress in global health, with vulnerable populations being particularly at risk.

As a result of an independent committee’s determination, the study has been discontinued.

Kei Sato, PhD, provides insights into the factors driving the spread and immune resistance of the LP.8.1 SARS-CoV-2 variant across different countries.

An inoculum effect in methicillin-susceptible S aureus infective endocarditis is suspected factor in higher all-cause 30-day mortality with cephazolin treatment than with oxacillin.

Carlien Pohl-Albertyn's, PhD research highlights the role of the South African brown locust in the transmission and survival of the emerging pathogen Candida auris.

A decreasing number of researchers and open positions for infectious disease clinicians and limited residency matches are underlying issues that should be addressed to meet the needs around antimicrobial development and clinical care. Amesh Adalja, MD, FIDSA, discusses some of the challenges behind it.

Hannah Pye, PhD and Evelien Adriaenssens, PhD explore the potential of phages in combating antimicrobial resistance and advancing health across human, animal, and environmental domains.

Twenty-four cases have been identified within the last two weeks, and 22 of those cases are in children. Nine of the cases have required hospitalization.

Professor Gordon Ramage, BSc, PhD, discusses the increasing impact of fungal biofilms, new treatment options, and the need for enhanced detection methods.

The new version of its molecular test targets the causes of gastroenteritis.

Heather Platt, MD, discusses Merck’s latest achievement with Capvaxive and its potential to significantly reduce invasive pneumococcal disease and pneumonia in high-risk adult populations across Europe.